K.N. Dzhalilov*, Z.A. Kadirov, U.A. Magomedova, K.A. Gashimova, T.V. Tsarueva, D.N. Dzhalilova and G.M. Gaziev

Federal State Budgetary Educational Institution of Higher Education "Dagestan State Medical University" of the Ministry of Health of the Russian Federation, Makhachkala, Russian Federation

*Corresponding Author: K.N. Dzhalilov, Assistant of the Department of Urology, DSMU of the Ministry of Health of the Russian Federation, Makhachkala, Russian Federation.

Received: May 05, 2023; Published: October 15, 2024

Abstract

The study included 102 patients of the older age group (mean age 70.5±1.7 years) with a clinical and laboratory diagnosis of recurrent chronic bacterial prostatitis complicated by prostatic hyperplasia. Two equal groups of 51 people were formed: main and comparison. Patients of the main group received fluoroquinolone levofloxacin 500 mg once a day for 4 weeks, bifiform probiotic 2 caps. 2 times a day for 4 weeks, enzyme Chymotripsin, immunomodulator polyoxidonium (rectal suppositories No. 10), antioxidant complex "Selzinc plus" 1 tab. per day for 4 weeks, drugs that improve hemodynamics and microcirculation in the prostate, inhibitors of 5-α reductase. Patients in the comparison group received standard therapy. Three visits were scheduled: baseline screening and 1 and 3 months after completion of treatment. Efficacy and safety of complex antibacterial and standard therapy was assessed by analyzing the average clinical and laboratory data of the International Questionnaires IPSS, NIH - CPSI, IIEF-5, Qol, the features of the clinical course of the disease depending on the treatment regimens used.

The results of this study demonstrate the efficacy and safety of comprehensive antibiotic therapy compared to standard antibiotic therapy. Patients in the main group had a mean score almost twice as high as those in the comparison group. The results of this study allow the use of complex antibacterial therapy with the inclusion of an immunomodulator, polyenzyme and antioxidant complex in the treatment of older patients with recurrent chronic bacterial prostatitis complicated by prostatic hyperplasia.

 Keywords: Patients; Older Age Group; Prostatitis; Antibiotic; Polyenzyme; Immunomodulator; Antioxidant

References

1. Clinical recommendation of the European Association of urologists. Moscow, 2019: 300. Russian (Clinical guidelines of the European Association of Urology) (2019).
2. Kogan MI., et al. “Microbiota of prostate secretion: comparative analysis of chronic prostatitis of categories II and III”. Urology 2 (2020): 16-22.
3. Arora HC., et al. “Gut microbiota and chronic pelvic pain syndrome”. Annals of Translational Medicine 2 (2017): 30-32.
4. Breser ML., et al. “Immunological mechanisms underlying chronic pelvic pain and prostate inflammation in chronic pelvic pain syndrome”. Frontiers in Immunology 8 (2017): 808.
5. Ibishev HS., et al. “Symptoms of the lower urinary tract with chronic pelvic pain syndrome III A and III B in connection with affective pathology. Mental disorders from understanding to correction and support: conference proceeding”. Rostov - on - Don. (2018): 122-125.
6. Davidov MI. “Sexual dysfunction in patients with chronic prostatitis and its correction”. Urology 1 (2020): 51-58.
7. Mironov Ayu and Shepelin IA. “Biofilms: a reference book of a bacteriologist”. Moscow: Typography Copying LLC. (2021): 161.
8. Mikhailova EA., et al. “The ability of Escherichia coli to form biofilms in the presence of aluminum oxide nanoparticles”. Clinical Laboratory Diagnostics6 (2017): 381-384.
9. Khryanin AA and Knorring GYu. “Modern concepts of biofilms of microorganisms”. Pharmateka 6 (2020): 34-42.
10. Bjarnsholt T. “The role of bacterial biofilm”. APMIS136 (2013): 1-51.

Citation

Citation: K.N. Dzhalilov., et al. “On the Efficacy and Safety of Comprehensive Antibiotic Therapy in Elderly Patients with Relapsing Chronic Bacterial Prostatitis Associated by Prostatic Hyperplasia”.Acta Scientific Medical Sciences 8.11 (2024): 96-100.

Copyright

Copyright: © 2024 K.N. Dzhalilov., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.